Home › Funds › Merck & Co., Inc. › EVAX

Merck & Co., Inc. position in EVAX

EVAXION AS · Health Care

Merck & Co., Inc. reported holding 1,214,126 shares of EVAX (EVAXION AS) in its Q3 2026 13F filing — a position valued at US$4.0M, representing 0.49% of its reported portfolio and ranking #9 among its reported holdings. Merck & Co., Inc. has disclosed EVAX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)1.21M sh
Reported value held$3.98M
Portfolio Weight0.49%
First reportedQ4 2024
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Merck & Co., Inc.'s EVAX position evolved

Merck & Co., Inc. first disclosed a stake in EVAX in Q4 2024 at 542,279 shares (US$458K). The position peaked in Q4 2025 at 1,214,126 shares, worth US$5.8M. Across 8 filings, Merck & Co., Inc. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,214,126 shares valued at US$4.0M. Notable position changes include a 124% increase in Q1 2025 (shares rose 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 542.28K $458.44K New
Q1 2025 1.21M $2.25M Add
Q2 2025 1.21M $2.97M Hold
Q3 2025 1.21M $4.57M Hold
Q4 2025 1.21M $5.79M Hold
Q1 2026 1.21M $4.52M Hold
Q2 2026 1.21M $3.76M Hold
Q3 2026 1.21M $3.98M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EVAX and 13F data

EVAX (EVAXION AS) is a Health Care company. 19 other funds we track also report a position in EVAX. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EVAX

No other tracked fund reports a position in EVAX.

All EVAX fund holders →

FAQ

How long has Merck & Co., Inc. held EVAX?

Merck & Co., Inc. has disclosed EVAX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Merck & Co., Inc.'s current position in EVAX?

As of Q3 2026, Merck & Co., Inc. holds 1.21M shares of EVAX (EVAXION AS), valued at $3.98M, representing 0.49% of its reported portfolio and ranking #9.

Has Merck & Co., Inc. been buying or selling EVAX?

In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in EVAX. The position peaked in Q4 2025 at 1.21M shares.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.